Analyst interview with Ziccum's CEO on new project and expanding business dialogues

In a Swedish video interview, Ziccum’s CEO Ann Gidner answers questions from analyst Jonathan Furelid on the topic of business dialogues and agreements.

Apart from elaborating on the significance of the recently concluded Feasibility Study Agreement with ReCode Therapeutics, a leader in the booming mRNA field, Ann Gidner also concludes on the successful completion of the first stage of the Big Pharma II Feasibility Study. Furthermore, Ziccum’s CEO underscores the increasing industry-wide interest generated by Ziccum’s technology, LaminarPaceTM, as evidenced by the growing number of leading industry players reaching out to Ziccum.

Please watch the full interview (in Swedish) here: https://youtu.be/-dnOT8oFLHs

Datum 2024-07-02, kl 08:30
Källa MFN
Kom igång med ditt sparande på bara några minuter! Hos Avanza handlar du aktier från 0 kr på Stockholmsbörsen och får tillbaka alla fondavgifter (ja, alla!) upp till 50 000 kr i samlat sparande. Kanske är det därför Avanza har Sveriges nöjdaste sparare 15 år i rad.
Investeringar innebär en risk